Interim Assessement Report
The EMA review was started by the Agency’s Committee for Medicinal Products for Human Use (CHMP) to support decision-making by health authorities. This first interim report includes information on seven experimental medicines intended for the treatment of people infecte...d with the Ebola virus:
BCX4430 (Biocryst);
Brincidofovir (Chimerix);
Favipiravir (Fujifilm Corporation/Toyama);
TKM-100802 (Tekmira);
AVI-7537 (Sarepta);
ZMapp (Leafbio Inc.);
Anti-Ebola F(ab’)2 (Fab’entech).
The amount of information available for the seven treatments is highly variable. For some compounds there is no data from use in human subjects available. A small number of treatments have been administered to patients in the current Ebola outbreak as compassionate use. Finally, there are also medicines included in this review that have already been studied in humans, albeit for the treatment of other viral diseases.
more
Ebola interventions: The intervention to combat Ebola aims to stop human-to-human transmission. The package is composed of five elements necessary to control the spread of the disease: care to patients, contact monitoring, safe burials, laboratory support and social mobilisation.
The document al...so describes key information on Ebola virus disease, patient care, contact tracing and monitoring, safe and dignified burial, laboratory diagnosis.
more
Glob Health Sci Pract February 1, 2014 vol. 2 no. 1 p. 103-116
Promoting People's Health to Enhance Social-economic Development
Document on key points needed to design, manage, deliver and evaluate training
You can also find a spanish and french version here: http://reprolineplus.org/resources/training-works-what-you-need-know-about-managing-designing-delivering-and-evaluating-group
Summary of research into the consequences of the Ebola outbreak for children and communities in Liberia and Sierra Leone